Announcement on Convening Performance Briefing for 2025 and Q1 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Convening Performance Briefing for 2025 and Q1 2026
Filed with SSE · · 3 pages · Chinese
Release
Zhuzhou Qianjin Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhuzhou Qianjin Pharmaceutical
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Obtaining Drug Registration Certificate by the Company and Its Subsidiary
- Announcement on Achievement of 2025 Performance Commitment on Purchasing Asset through Shares Issuance and Cash Payment and Related Party Transactions
- Announcement on Preliminary Earnings Estimate for 2025
- Announcement on Resignation of Director and Election of Employee Director
Later from Zhuzhou Qianjin Pharmaceutical
- Announcement on Outline of the Performance Briefing for 2025 and Q1 2026
- Announcement on Obtaining Drug Registration Certificate by Subsidiary
- Announcement on Implementation of Dividend Distribution for 2025
- Announcement on Change of Independent Financial Advisor Sponsor for Continuous Supervision
- Announcement on Acquisition of Drug Registration Certificate by Subsidiaries
Follow Zhuzhou Qianjin Pharmaceutical into a list and get an email when it puts out news.
Follow Zhuzhou Qianjin Pharmaceutical